Historical Valuation
GoodRx Holdings Inc (GDRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.18 is considered Undervalued compared with the five-year average of 109.82. The fair price of GoodRx Holdings Inc (GDRX) is between 4.37 to 5.77 according to relative valuation methord. Compared to the current price of 2.80 USD , GoodRx Holdings Inc is Undervalued By 35.94%.
Relative Value
Fair Zone
4.37-5.77
Current Price：2.80
35.94%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
GoodRx Holdings Inc (GDRX) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of 2.94 , the current P/B ratio is approximately -46.95% higher. Relative to its 5-year average P/B ratio of 6.84, the current P/B ratio is about -77.17% higher. GoodRx Holdings Inc (GDRX) has a Forward Free Cash Flow (FCF) yield of approximately 19.00%. Compared to its 3-year average FCF yield of 7.89%, the current FCF yield is approximately 140.64% lower. Relative to its 5-year average FCF yield of 5.98% , the current FCF yield is about 217.61% lower.
P/B
Median3y
2.94
Median5y
6.84
FCF Yield
Median3y
7.89
Median5y
5.98
Competitors Valuation Multiple
AI Analysis for GDRX
The average P/S ratio for GDRX competitors is 2.73, providing a benchmark for relative valuation. GoodRx Holdings Inc Corp (GDRX.O) exhibits a P/S ratio of 1.18, which is -57.01% above the industry average. Given its robust revenue growth of 0.40%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for GDRX
1Y
3Y
5Y
Market capitalization of GDRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GDRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GDRX currently overvalued or undervalued?
GoodRx Holdings Inc (GDRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.18 is considered Undervalued compared with the five-year average of 109.82. The fair price of GoodRx Holdings Inc (GDRX) is between 4.37 to 5.77 according to relative valuation methord. Compared to the current price of 2.80 USD , GoodRx Holdings Inc is Undervalued By 35.94% .
What is GoodRx Holdings Inc (GDRX) fair value?
GDRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GoodRx Holdings Inc (GDRX) is between 4.37 to 5.77 according to relative valuation methord.
How does GDRX's valuation metrics compare to the industry average?
The average P/S ratio for GDRX's competitors is 2.73, providing a benchmark for relative valuation. GoodRx Holdings Inc Corp (GDRX) exhibits a P/S ratio of 1.18, which is -57.01% above the industry average. Given its robust revenue growth of 0.40%, this premium appears unsustainable.
What is the current P/B ratio for GoodRx Holdings Inc (GDRX) as of Jan 10 2026?
As of Jan 10 2026, GoodRx Holdings Inc (GDRX) has a P/B ratio of 1.56. This indicates that the market values GDRX at 1.56 times its book value.
What is the current FCF Yield for GoodRx Holdings Inc (GDRX) as of Jan 10 2026?
As of Jan 10 2026, GoodRx Holdings Inc (GDRX) has a FCF Yield of 19.00%. This means that for every dollar of GoodRx Holdings Inc’s market capitalization, the company generates 19.00 cents in free cash flow.
What is the current Forward P/E ratio for GoodRx Holdings Inc (GDRX) as of Jan 10 2026?
As of Jan 10 2026, GoodRx Holdings Inc (GDRX) has a Forward P/E ratio of 19.12. This means the market is willing to pay $19.12 for every dollar of GoodRx Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for GoodRx Holdings Inc (GDRX) as of Jan 10 2026?
As of Jan 10 2026, GoodRx Holdings Inc (GDRX) has a Forward P/S ratio of 1.18. This means the market is valuing GDRX at $1.18 for every dollar of expected revenue over the next 12 months.